达安基因：2025年预计净亏损6.07亿-8.65亿元

Core Viewpoint - The company DaAn Gene expects a net profit attributable to shareholders of between -865 million to -607 million yuan for 2025, an improvement from -925 million yuan in the same period last year [1] Financial Performance - The expected net profit after deducting non-recurring items is projected to be between -938 million to -658 million yuan, compared to -823 million yuan in the previous year [1] - The performance fluctuation is primarily due to decreased revenue from market demand, centralized procurement policies, and tax rate adjustments, leading to operational losses [1] Investment and Asset Management - Improved performance from joint ventures has resulted in increased investment income [1] - The company has strengthened the collection of accounts receivable, leading to a reduction in related credit impairment losses, although asset impairment losses have increased [1] - The fair value of other non-current financial assets has risen, with non-recurring gains before tax increasing by approximately 180 million yuan [1]